Francisco Trust Under Agreemen Sells 41,143 Shares of Dyadic International (NASDAQ:DYAI) Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 41,143 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $1.84, for a total value of $75,703.12. Following the sale, the insider directly owned 3,455,764 shares of the company’s stock, valued at approximately $6,358,605.76. This represents a 1.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Dyadic International Stock Performance

NASDAQ:DYAI opened at $1.06 on Wednesday. The company has a debt-to-equity ratio of 4.08, a current ratio of 2.42 and a quick ratio of 2.42. The firm has a market cap of $38.63 million, a price-to-earnings ratio of -4.61 and a beta of 1.15. The firm’s fifty day moving average price is $0.78 and its 200 day moving average price is $0.83. Dyadic International Inc. has a 1-year low of $0.65 and a 1-year high of $1.35.

Dyadic International (NASDAQ:DYAI) last released its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The firm had revenue of $1.11 million during the quarter, compared to analyst estimates of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. On average, sell-side analysts expect that Dyadic International Inc. will post 0.13 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $3.00.

Key Headlines Impacting Dyadic International

Here are the key news stories impacting Dyadic International this week:

• Positive Sentiment: Dyadic said global collaborations are continuing to validate its C1 platform and expand commercial potential, including work tied to Ebola preparedness, which may improve the long-term outlook for its technology. Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
• Neutral Sentiment: Recent quarterly results were mixed: revenue came in above expectations, but EPS missed estimates, keeping attention on whether Dyadic can convert its technology into sustained profitability.
• Negative Sentiment: Major shareholder Francisco Trust Under Agreement disclosed multiple recent stock sales, which may pressure sentiment because insider selling can raise concerns about near-term confidence in the shares.

Hedge Funds Weigh In On Dyadic International

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Apis Capital Advisors LLC acquired a new stake in shares of Dyadic International in the third quarter valued at about $1,817,000. Marathon Capital Management acquired a new position in Dyadic International during the third quarter worth about $41,000. Geode Capital Management LLC increased its holdings in Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new stake in shares of Dyadic International during the 3rd quarter valued at approximately $190,000. Finally, Bank of America Corp DE lifted its position in shares of Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 26,965 shares during the period. 27.95% of the stock is owned by institutional investors and hedge funds.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.